Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3381916 +/- lodapolimab in solid tumors
NCT03343613Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2017
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of LY3381916 in solid tumor, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and 1 more (6 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with Dose Limiting Toxicities. Started Nov 2017; status: terminated.
02
Drugs
LY3381916
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03343613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03343613.